欢迎访问中国科学院大学学报,今天是
综述

蛋白质同型半胱氨酸化与动脉粥样硬化机制

  • 吴云飞 ,
  • 钟良玮
展开
  • 中国科学院研究生院生命科学学院, 京 100049

收稿日期: 2008-03-31

  修回日期: 2008-08-12

  网络出版日期: 2009-03-15

基金资助

国家自然科学基金(30470374)、中国科学院院长基金和中国科学院研究生院启动基金资助项目 

Protein homocysteinylation and mechanisms of atherosclerosis

  • WU Yun-Fei ,
  • ZHONG Liang-Wei
Expand
  • College of Life Sciences, Graduate University of the Chinese Academy of Sciences, Beijing 100049, China

Received date: 2008-03-31

  Revised date: 2008-08-12

  Online published: 2009-03-15

摘要

动脉粥样硬化是严重危害人类生命健康的世界性疾病,因发病机制至今未明,尚无有效防治措施.大量研究证明,高同型半胱氨酸血症是引起动脉粥样硬化的独立危险因素.高同型半胱氨酸血症与氧化应激、内质网应激、血管内皮细胞损伤及血液粘稠度增高之间的密切关系已有大量文献报道,但其具体机制有待阐明.综述简要介绍了近年来在国际上颇受关注的蛋白质同型半胱氨酸化.围绕抗氧化酶、内质网蛋白、凝血因子、低密度脂蛋白,以及与钙信号有关的蛋白被同型半胱氨酸化的研究发现,从同型半胱氨酸及其衍生物同型半胱氨酸巯基内酯对蛋白质的共价修饰反应,到使分子结构与理化性质发生改变的生化机制,阐述了这种修饰与动脉粥样硬化斑块形成的关系.

本文引用格式

吴云飞 , 钟良玮 . 蛋白质同型半胱氨酸化与动脉粥样硬化机制[J]. 中国科学院大学学报, 2009 , 26(2) : 145 -151 . DOI: 10.7523/j.issn.2095-6134.2009.2.001

Abstract

Atherosclerosis is a world-wide disease with severe effects on human health. Although it remains unclear about the pathological mechanisms of atherosclerosis that can not be efficiently prevented and treated so far, a large body of evidence suggests that increased level of plasma homocysteine is an independent risk factor for atherosclerosis. Numerous studies have found a close relationship between hyperhomocysteinemia and oxidative stress, endoplasmic reticulum stress, endothelial cell injury as well as increased viscosity of blood, but the underlying mechanisms are largely unknown. This brief review introduces protein homocysteinylation, to which more and more researchers abroad begin to pay attention. We mainly focus on homocysteinylation of antioxidant enzymes, endoplasmic reticulum resident proteins, coagulation factors, low-density lipoprotein and calcium signaling-related proteins. To elucidate an importance of protein homocysteinylation in the development of atherosclerotic plaque, we also describe how homocysteine and its derivative homocysteine thiolactone covalently modify proteins, by which the structure and physical-chemical properties of target molecules are altered.

参考文献


[1] McCully KS. Hyperhomocysteinemia and arteriosclerosis: historical perspectives. Clin Chem Lab Med, 2005, 43(10):980~986

[2] Beltowski J. Protein homocysteinylation: a new mechanism of atherogenesis? Postepy Hig Med Dosw (Online), 2005, 59:392~404

[3] Jakubowski H. Molecular basis of homocysteine toxicity in humans. Cell Mol Life Sci, 2004, 61(4):470~487

[4] Cook JW, Yin Q, Malinow MR, et al. Hyperhomocyst(e)inemia induces accelerated transplant vascular sclerosis in syngeneic and allogeneic rat cardiac transplants. Am J Transplant, 2002, 2(3):244~251

[5] Jakubowski H. The determination of homocysteine-thiolactone in biological samples. Anal Biochem, 2002, 308(1):112~119

[6] Jakubowski H. Translational accuracy of aminoacyl-tRNA synthetases: implications for atherosclerosis. J Nutr, 2001, 131(11):2983S~2987S

[7] Jakubowski H. Proofreading in vivo: editing of homocysteine by methionyl-tRNA synthetase in the yeast Saccharomyces cerevisiae. Embo J, 1991, 10(3):593~598

[8] Jakubowski H. Metabolism of homocysteine thiolactone in human cell cultures. Possible mechanism for pathological consequences of elevated homocysteine levels. J Biol Chem, 1997, 272(3):1935~1942

[9] Glowacki R, Jakubowski H. Cross-talk between Cys34 and lysine residues in human serum albumin revealed by N-homocysteinylation. J Biol Chem, 2004, 279(12):10864~10871

[10] Glushchenko AV, Jacobsen DW. Molecular targeting of proteins by L-homocysteine: mechanistic implications for vascular disease. Antioxid Redox Signal, 2007, 9(11):1883~1898

[11] Jakubowski H. Homocysteine is a protein amino acid in humans. Implications for homocysteine-linked disease. J Biol Chem, 2002, 277(34):30425~30428

[12] Dayal S, Arning E, Bottiglieri T, et al. Cerebral vascular dysfunction mediated by superoxide in hyperhomocysteinemic mice. Stroke, 2004, 35(8):1957~1962

[13] Dayal S, Brown KL, Weydert CJ, et al. Deficiency of glutathione peroxidase-1 sensitizes hyperhomocysteinemic mice to endothelial dysfunction. Arterioscler Thromb Vasc Biol, 2002, 22(12):1996~2002

[14] Upchurch GR Jr, Welch GN, Fabian AJ, et al. Homocyst(e)ine decreases bioavailable nitric oxide by a mechanism involving glutathione peroxidase. J Biol Chem, 1997, 272(27):17012~17017

[15] Handy DE, Zhang Y, Loscalzo J. Homocysteine down-regulates cellular glutathione peroxidase (GPx1) by decreasing translation. J Biol Chem, 2005, 280(16):15518~15525

[16] Suematsu N, Ojaimi C, Kinugawa S, et al. Hyperhomocysteinemia alters cardiac substrate metabolism by impairing nitric oxide bioavailability through oxidative stress. Circulation, 2007, 115(2):255~262

[17] Barbato JC, Catanescu O, Murray K, et al. Targeting of metallothionein by L-homocysteine: a novel mechanism for disruption of zinc and redox homeostasis. Arterioscler Thromb Vasc Biol, 2007, 27(1):49~54

[18] Pitoulias GA, Tachtsi MD, Tsiaousis PZ, et al. Hyperhomocysteinemia and hypercoagulable state in carotid plaque evolution. Novel risk factors or coincidental risk predictors? Int Angiol, 2007, 26(3):270~278

[19] Sauls DL, Lockhart E, Warren ME, et al. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. Biochemistry, 2006, 45(8):2480~2487

[20] Hajjar KA, Mauri L, Jacovina AT, et al. Tissue plasminogen activator binding to the annexin Ⅱ tail domain. Direct modulation by homocysteine. J Biol Chem, 1998, 273(16):9987~9993

[21] Ling Q, Hajjar KA. Inhibition of endothelial cell thromboresistance by homocysteine. J Nutr, 2000, 130(2S Suppl):373S~376S

[22] Gotlieb AI. Smooth muscle and endothelial cell function in the pathogenesis of atherosclerosis. Can Med Assoc J, 1982,126(8):903~908

[23] Majors AK, Sengupta S, Willard B, et al. Homocysteine binds to human plasma fibronectin and inhibits its interaction with fibrin. Arterioscler Thromb Vasc Biol, 2002, 22(8):1354~1359

[24] Liu G, Nellaiappan K, Kagan HM. Irreversible inhibition of lysyl oxidase by homocysteine thiolactone and its selenium and oxygen analogues. Implications for homocystinuria. J Biol Chem, 1997, 272(51):32370~32377

[25] Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost, 2005, 3(8):1646~1654

[26] Werstuck GH, Lentz SR, Dayal S, et al. Homocysteine-induced endoplasmic reticulum stress causes dysregulation of the cholesterol and triglyceride biosynthetic pathways. J Clin Invest, 2001, 107(10):1263~1273

[27] Zhang C, Cai Y, Adachi MT, et al. Homocysteine induces programmed cell death in human vascular endothelial cells through activation of the unfolded protein response. J Biol Chem, 2001, 276(38):35867~35874

[28] Ferguson E, Hogg N, Antholine WE, et al. Characterization of the adduct formed from the reaction between homocysteine thiolactone and low-density lipoprotein: antioxidant implications. Free Radic Biol Med, 1999, 26(7-8):968~977

[29] Zinellu A, Zinellu E, Sotgia S, et al. Factors affecting S-homocysteinylation of LDL apoprotein B. Clin Chem, 2006, 52(11):2054~2059

[30] Vignini A, Nanetti L, Bacchetti T, et al. Modification induced by homocysteine and low-density lipoprotein on human aortic endothelial cells: an in vitro study. J Clin Endocrinol Metab, 2004, 89(9):4558~4561

[31] Plank MJ, Wall DJ, David T. Atherosclerosis and calcium signalling in endothelial cells. Prog Biophys Mol Biol, 2006, 91(3):287~313

[32] Dalton ML, Gadson PF Jr, Wrenn RW, et al. Homocysteine signal cascade: production of phospholipids, activation of protein kinase C, and the induction of c-fos and c-myb in smooth muscle cells. Faseb J, 1997, 11(8):703~711

[33] Okatani Y, Wakatsuki A, Reiter RJ. Melatonin counteracts potentiation by homocysteine of KCL-induced vasoconstriction in human umbilical artery: relation to calcium influx. Biochem Biophys Res Commun, 2001, 280(3):940~944

[34] Zhang HS, Xiao JH, Cao EH, et al. Homocysteine inhibits store-mediated calcium entry in human endothelial cells: evidence for involvement of membrane potential and actin cytoskeleton. Mol Cell Biochem, 2005, 269(1-2):37~47

[35] Chang L, Zhao J, Xu J, et al. Effects of taurine and homocysteine on calcium homeostasis and hydrogen peroxide and superoxide anions in rat myocardial mitochondria. Clin Exp Pharmacol Physiol, 2004, 31(4):237~243

[36] Dickhout JG, Sood SK, Austin RC. Role of endoplasmic reticulum calcium disequilibria in the mechanism of homocysteine-induced ER stress. Antioxid Redox Signal, 2007

[37] Mujumdar VS, Aru GM, Tyagi SC. Induction of oxidative stress by homocyst(e)ine impairs endothelial function. J Cell Biochem, 2001, 82(3):491~500

[38] Suhara T, Fukuo K, Yasuda O, et al. Homocysteine enhances endothelial apoptosis via upregulation of Fas-mediated pathways. Hypertension, 2004, 43(6):1208~1213

[39] Mercie P, Garnier O, Lascoste L, et al. Homocysteine-thiolactone induces caspase-independent vascular endothelial cell death with apoptotic features. Apoptosis, 2000, 5(5):403~411

文章导航

/